DISCONTINUATION OF CREATINE KINASE, MB ISOENZYME QUANTITATIVE TEST

Annu Khajuria, PhD and Gene Shaw, MD,
Division of Laboratory Medicine, Marshfield Labs.

Effective April 15, 2014, Creatine Kinase, MB Isoenzyme Quantitative Test (Test Code: CKMB) will be discontinued in the Marshfield Clinic system, and at Diagnostic & Treatment Center, Lakeview Medical Center, and Flambeau Hospital.

TEST INFORMATION

Test Name: Creatine Kinase, MB Isoenzyme Quantitative Test
Test Code: CKMB

Before the advent of cardiac troponin (cTn) testing, creatine kinase, MB (CKMB) was the most widely used cardiac marker. However, per current recommendations (Third Definition of Myocardial Infarction, 2012), when cTn is available, CKMB should not be used for the diagnosis of acute myocardial infarction. CKMB does not have equivalent sensitivity or specificity compared to cTn. There is no clinical situation in which CKMB is superior (e.g., suspected reinfarction, after interventional cardiac procedures or surgery). Current cTn assays have excellent clinical sensitivity for detecting acute coronary events; elevations can generally be observed as early as two hours after onset of symptoms.

After April 15, 2014, CKMB will be available only as a send-out test to Mayo Laboratories and will require approval from a clinical chemist or pathologist.

For queries or for additional information, contact Dr. Annu Khajuria at 800-222-5835.
REFERENCES

